Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference and health economics of self/partner vs healthcare professional administration of lanreotide Autogel in neuroendocrine tumours
2007-006514-42Phase 4Completed
- Sponsor
- Ipsen
- Start
- Dec 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lanreotide in neuroendocrine tumour (NET) and Carcinoid Syndrome (CS) (2 arms), sponsored by Ipsen. Primary endpoint: Patient preference for administration method at last visit. Started Dec 2007; status: completed.
02
Drugs
lanreotide
03
Conditions
neuroendocrine tumour (NET)Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on 2007-006514-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006514-42.